Close menu




June 12th, 2023 | 08:00 CEST

Disruption! From now on, everything will be different: PayPal, BYD, BioNXt

  • Biotechnology
  • Pharma
  • Electromobility
  • Software
Photo credits: pixabay.com

What is now called disruption in the startup scene has always existed. It refers to creative destruction, cutting old ties and rethinking things from the ground up. Companies that create marketable products in this way have an edge over the competition - and score points on the market with their uniqueness. We present three titles.

time to read: 3 minutes | Author: Nico Popp
ISIN: PAYPAL HDGS INC.DL-_0001 | US70450Y1038 , BYD CO. LTD H YC 1 | CNE100000296 , Bionxt Solutions Inc. | CA0909741062

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    PayPal's recipe for success: Easier, faster, cheaper

    When the payment service PayPal was founded in Palo Alto, California, in 1998, most people in Germany still dialled into the Internet via modem or ISDN. Marketplaces, such as online auction houses, only spread gradually and lived above all from their innovative power. Peter Thiel's team quickly realized that the comparatively young Internet would soon be of great commercial importance and that a payment service was needed. The following years can be summarized quickly: Since 2004, PayPal has been available in Germany, and since 2007, the Company has also had a banking licence in Europe.

    Compared to traditional financial institutions, PayPal quickly gained the upper hand on the internet - even though credit cards were initially the number one means of payment online. However, problems with security and handling drove customers to PayPal in droves. The cooperation with eBay, to which PayPal even belonged for a time, also contributed to the spread of the service. Those who regularly bought things at auction soon no longer wanted to use bank transfers and appreciated buyer protection. Today, PayPal is so strongly positioned in the market that one can trust the share despite recession worries. Despite the share price losses, PayPal is still up more than 65% over eight years.

    BYD: Flat screen instead of sports chassis

    The Chinese carmaker BYD is also something of a revolutionary. In the same period, the share even generated a return of a whopping 429% - and that despite the fact that the share is also already trading well below its all-time high. Why is that? BYD was an early adopter of electric mobility. This spring, it even stopped building internal combustion vehicles altogether. Another unique selling point of BYD is that the Company relies heavily on connectivity and technical bells and whistles. Large displays, WLAN, Bluetooth and lots of LEDs are more convincing to Chinese customers than a tight chassis. Why this is so is not surprising - after all, cars on China's roads send data to the authorities every thirty seconds. Driving pleasure is then quickly redefined. But back to BYD: As a promising company in the most important car market, the share is naturally highly rated. Whether the exit of Berkshire Hathaway or worries about a trade war between East and West: this market position is convincing and unique.

    BioNxt does it better and cheaper

    Completely free of worries about trade wars or financial crises are shareholders of the Canadian biotech BioNxt. The Company has positioned itself in various promising areas and sees itself as a problem solver within the healthcare system. The German subsidiary Vektor Pharma TF GmbH has developed a patch around the well-known Parkinson's drug rotigotine that can compete with original preparations in studies. A clinical trial of the product is currently underway, with the results expected by late summer. Only a few months ago, a court in the US cleared the way for generics in this very field. Also, a few months ago, BioNxt received an order to produce an orally soluble product. To fulfil this order, the Company has invested in a coating and cutting machine at its Biberach site.

    The business field of innovative dosage forms, which is also gaining commercial momentum, is extremely promising for BioNxt Solutions. The Company does not rule out acting as a contract manufacturer in other areas in the future. The dose can be adjusted depending on how effectively an active substance reaches the patient. This saves costs and strikes a chord with already cash-strapped healthcare systems worldwide. The incipient commercialization can be an opportunity for investors. In parallel, BioNxt is involved in the diagnostics sector, offering self-tests related to oral health. There is already a letter of intent for the production of biosensor products for testing inflammatory diseases of the oral cavity, such as those that occur as a side effect of drugs for opioid abuse, for the US market.


    Companies that have rethought tried-and-tested products from the ground up are also successful on the stock market - good examples are PayPal and BYD. BioNxt Solutions has made significant progress in the commercialization of its product range in recent months. If the positive trend continues and the figures are right, the share, which currently represents an enterprise value of around CAD 58 million, should be seen by many investors with new eyes.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST

    BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?

    • Biotechnology
    • Biotech
    • Pharma

    On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.

    Read

    Commented by André Will-Laudien on July 24th, 2024 | 07:00 CEST

    Averting power outages, starting the battery revolution! BASF, Altech Advanced Materials, BYD, and VW

    • Batteries
    • Hydrogen
    • BatteryMetals
    • Electromobility
    • renewableenergies

    Varta is undergoing a complete restructuring and reorganization, likely leaving legacy shareholders empty-handed. The back and forth since 2023 has given the German SME sector an increasingly unsettling look. The environment is challenging, and only the strongest will survive the looming storm. Traces of Habeck's poor planning can also be seen in the energy transition. Instead of fully utilizing renewable energies, six new gas-fired power plants are now being planned, which will, of course, be powered by hydrogen. This draws investors' attention back to battery storage systems, as they are needed to successfully store surplus energy. Where do the opportunities lie for resourceful investors?

    Read

    Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST

    BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions

    • Biotechnology
    • Pharma
    • Biotech

    Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.

    Read